{"id":"NCT01187953","sponsor":"Veloxis Pharmaceuticals","briefTitle":"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx","officialTitle":"Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2013-03","completion":"2014-03","firstPosted":"2010-08-24","resultsPosted":"2015-05-29","lastUpdate":"2016-05-18"},"enrollment":543,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Renal Failure"],"interventions":[{"type":"DRUG","name":"Prograf (tacrolimus)","otherNames":["tacrolimus"]},{"type":"DRUG","name":"LCP-Tacro","otherNames":["Tacrolimus modifed-release"]}],"arms":[{"label":"LCP-Tacro","type":"EXPERIMENTAL"},{"label":"Prograf (tacrolimus)","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of LCP-Tacro (tacrolimus) Tablets administered once-a-day compared to Prograf (tacrolimus) Capsules twice-a-day as immunosuppression for the prevention of organ rejection in newly transplanted adult kidney transplant recipients. Patients will be treated for a 12 month study period followed by a 12 month, blinded extension treatment period To show that LCP-Tacro Tablets are clinically similar to Prograf Capsules in the prevention of acute rejection.","primaryOutcome":{"measure":"The Primary Efficacy Endpoint for the Study is the Proportion of Treatment Failures Within 12 Months After Randomization to Study Drug.","timeFrame":"360 days","effectByArm":[{"arm":"LCP-Tacro","deltaMin":8,"sd":null},{"arm":"Prograf (Tacrolimus)","deltaMin":8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":">0.999"},{"comp":"OG000 vs OG001","p":"0.821"},{"comp":"OG000 vs OG001","p":"0.900"},{"comp":"OG000 vs OG001","p":">0.999"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":86,"countries":["United States","Argentina","Australia","Brazil","France","Germany","Italy","Mexico","New Zealand","Poland","Serbia","Singapore","South Korea","Spain","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":166,"n":268},"commonTop":["Diarrhoea","Urinary tract infection","Anaemia","Hypertension","Constipation"]}}